Related Experiment Videos
Possibilities of preventing otitis media by vaccination
Insights
Preventing childhood acute otitis media (AOME) is challenging as the current pneumococcal vaccine is ineffective in children under two. This is due to common pneumococcal strains having poor immunizing capacity in infants, necessitating a new vaccine approach.
Area of Science:
- Pediatrics
- Immunology
- Infectious Diseases
Background:
- Acute otitis media (AOME) is a common childhood infection.
- Pneumococcal bacteria are the primary cause of AOME.
- Current vaccines target pneumococcal types, but efficacy varies with age.
Purpose of the Study:
- To evaluate the effectiveness of the 14-valent pneumococcal capsular polysaccharide vaccine in preventing AOME in children.
- To identify limitations of the current vaccine in young children.
- To inform the development of improved AOME vaccines.
Main Methods:
- Analysis of existing data on pneumococcal serotypes in AOME cases.
- Assessment of antibody response to pneumococcal vaccine components in infants.
- Correlation of vaccine serotype prevalence with AOME incidence in different age groups.
Main Results:
- The most common pneumococcal types causing AOME are included in the current vaccine.
- However, the vaccine demonstrates poor immunizing capacity against the four most prevalent types in infants.
- Consequently, the vaccine provides limited protection against AOME in children under two years old.
Conclusions:
- The current pneumococcal vaccine has limited efficacy for preventing AOME in children under two.
- The poor immunizing capacity of key pneumococcal serotypes in infants is a significant barrier.
- Development of a new AOME vaccine targeting age-specific immunogenicity is crucial.
Abstract:
The prerequisites for preventing a considerable proportion of acute otitis media (AOME) of children are theoretically good--pneumococcal types/groups present in the available 14-valent pneumococcal capsular polysaccharide vaccine are the most common bacteria in AOME, and a good serum antibody response is followed by type-specific protection from infection. However, the four most common types/groups (= 2/3 of all pneumococci in AOME) have very poor immunizing capacity in infants, and therefore the vaccine offers little protection from AOME for children under the age of 2 years. This information should help towards an improved new vaccine for AOME.